There are few good COVID antivirals, but that could be changing

Sara Cherry of the Perelman School of Medicine spoke about the arduous process of developing antiviral drugs to treat COVID-19. “Most of the compounds that work in cells ultimately fail in animal studies for lots of reasons,” she said. Of the compounds that remain, just a few make it to the animal testing stage.

・ From Scientific American